RecruitingNot ApplicableNCT06632886

AI-Assisted Non-Contrast CT for Multi-Cancer Screening

A Prospective Cohort Study Evaluating the Utility of Artificial Intelligence-Assisted Non-Contrast Computed Tomography for Multi-Cancer Screening in Asymptomatic Individuals Undergoing Routine Health Examinations


Sponsor

Guo ShiWei

Enrollment

1,000,000 participants

Start Date

Oct 7, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening. The study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Subject is able and willing to provide informed consent and sign an informed consent form.
  • Subject has undergone an abdominal or chest non-contrast CT scan.

Exclusion Criteria3

  • Subject has been diagnosed with one of the following cancers within the last five years: lung, liver, stomach, colon, esophageal, pancreatic, or breast cancer;
  • Subject has any medical condition that contraindicates high-resolution MRI/CT/Endoscopy;
  • Subject cannot be followed up or is participating in other clinical trials.

Interventions

DIAGNOSTIC_TESTAI-Assisted Non-Contrast CT for Multi-Cancer Screening

Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.


Locations(1)

Changhai Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06632886


Related Trials